WACKER expands its production of cysteine
Acquires fermentation plant in Spain
Through the acquisition, WACKER is obtaining a production line with a fermentation capacity of 800 m3 from Antibióticos de León SLU in León (northern Spain). The Munich-based chemical company intends to invest a total of about €30 million to modernize the existing facility and add production equipment over the next few years, thereby creating some 35 new jobs at the site. The transaction is expected to close by year-end.
“The acquisition is a key step in strengthening our position as the global market and technology leader for fermentation-generated cysteine,” explained Auguste Willems of WACKER’s Executive Board, commenting on the investment. “This project is part of our strategy to increase the proportion of specialties in our total business and thus to continue our profitable growth. The acquisition gives us an ideal position to securely meet our customers’ growing demand for cysteine and to commercialize new fermenter products in the future.”
Juan Molins, Managing Director of Antibióticos de León, said: “This step is an excellent opportunity to use the spare ADL fermentation capacity, while it underscores the strategy of converting our installation in a cluster of activities with added value. We are happy that the WACKER Group is investing in León and are sure we have found the right partner to continue developing this site for a successful future.”
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.